Fatigue is the Most Important Symptom for Advanced Cancer Patients Who Have Had Chemotherapy

Cancer fatigue has been defined and described as an important problem. However, few studies have assessed the relative importance of fatigue compared with other patient symptoms and concerns. To explore this issue, the authors surveyed 534 patients and 91 physician experts from 5 NCCN member institutions and community support agencies. Specifically, they asked patients with advanced bladder, brain, breast, colorectal, head and neck, hepatobiliary/pancreatic, kidney, lung, ovarian, or prostate cancer or lymphoma about their “most important symptoms or concerns to monitor.” Across the entire sample, and individually for patients with 9 cancer types, fatigue emerged as the top-ranked symptom. Fatigue was also ranked most important among patients with 10 of 11 cancer types when asked to rank lists of common concerns. Patient fatigue ratings were most strongly associated with malaise (r = 0.50) and difficulties with activities of daily living, pain, and quality of life. Expert ratings of how much fatigue is attributable to disease versus treatment mostly suggested that both play an important role, with disease-related factors predominant in hepatobiliary and lung cancer, and treatment-related factors playing a stronger role in head and neck cancer.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Zeeshan Butt, PhD, Center on Outcomes, Research, and Education (CORE), Evanston Northwestern Healthcare, 1001 University Place, Suite 100, Evanston, lL 60201. E-mail: z-butt@northwestern.edu
  • 1.

    CellaDFTulskyDSGrayG. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol1993;11:570579.

    • Search Google Scholar
    • Export Citation
  • 2.

    WinninghamMLNailLMBurkeMB. Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum1994;21:2336.

  • 3.

    CellaD. Quality of life in cancer patients experiencing fatigue and anemia. Anemia in Oncology1998;24.

  • 4.

    WagnerLICellaD. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer2004;91:822828.

  • 5.

    IrvineDVincentLGraydonJE. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs1994;17:367378.

    • Search Google Scholar
    • Export Citation
  • 6.

    PrueGRankinJAllenJ. Cancer-related fatigue: a critical appraisal. Eur J Cancer2006;42:846863.

  • 7.

    GreenbergDB. Fatigue. In: Holland J ed.Psycho-Oncology. New York: Oxford University Press; 1998:485493.

  • 8.

    VogelzangNJBreitbartWCellaD. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol1997;34(3 Suppl 2):412.

    • Search Google Scholar
    • Export Citation
  • 9.

    ButtZWagnerLIBeaumontJL. Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy. Support Care Cancer2008;16:151159.

    • Search Google Scholar
    • Export Citation
  • 10.

    Von RoennJHPaiceJA. Control of common, non-pain cancer symptoms. Semin Oncol2005;32:200210.

  • 11.

    CellaDPaulDYountS. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest2003;21:526535.

    • Search Google Scholar
    • Export Citation
  • 12.

    RosenbloomSKYountSEYostKJ. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: measurement compliance with regulatory demands. In: Farquhar I Summers K Sorkin A eds.The Value of Innovation: Impacts on Health Life Quality and Regulatory Research. Oxford: Elsevier; 2007.

    • Search Google Scholar
    • Export Citation
  • 13.

    CellaDFBonomiAELeslieWT. Quality of life and nutritional well-being: measurement and relationship. Oncology1993;7(Suppl):105111.

  • 14.

    OkenMMCreechRHTormeyDC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol1982;5:649655.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 254 224 8
PDF Downloads 93 86 4
EPUB Downloads 0 0 0